Cognition

nTIDE November 2022 Jobs Report: People with disabilities continue to outperform people without disabilities in labor market

Retrieved on: 
Friday, December 2, 2022

EAST HANOVER, N.J., Dec. 2, 2022 /PRNewswire/ -- Job numbers rose again for people with disabilities, in contrast to people without disabilities, according to today's National Trends in Disability Employment – Monthly Update (nTIDE), issued by Kessler Foundation and the University of New Hampshire's Institute on Disability (UNH-IOD). People with disabilities continued to show strength in the labor market in November, as evidenced by the substantial rise in their employment-to-population ratio.

Key Points: 
  • People with disabilities continued to show strength in the labor market in November, as evidenced by the substantial rise in their employment-to-population ratio.
  • "Similar to last month, the employment-to-population ratio for people with disabilities increased and remains above historic highs.
  • Our new survey compares the workplaces of 2017 and 2022, revealing gains in recruiting, hiring, accommodating, and retaining employees with disabilities.
  • Kessler Foundation leads the nation in funding innovative programs that expand opportunities for employment for people with disabilities.

Stoke Therapeutics Presents Data from a Combined Interim Analysis of the Phase 1/2a MONARCH and ADMIRAL Studies of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2022 Annual Meeting

Retrieved on: 
Friday, December 2, 2022

A total of seven posters will be presented at the American Epilepsy Society (AES) 2022 Annual Meeting, December 2-6.

Key Points: 
  • A total of seven posters will be presented at the American Epilepsy Society (AES) 2022 Annual Meeting, December 2-6.
  • Dravet syndrome is a severe and progressive genetic epilepsy characterized by frequent, prolonged and refractory seizures beginning within the first year of life.
  • STK-001 represents an entirely new approach to treatment, one that aims to treat the syndrome, not just the seizures.
  • Topline data from a combined interim analysis of the Phase 1/2a MONARCH and ADMIRAL studies showed single and multiple doses of STK-001 up to 45mg were well-tolerated.

ANAVEX®2–73 (Blarcamesine) Phase 2B/3 Study Met Primary and Key Secondary Endpoints, Showing Statistically Significant Reduction of Clinical Decline in Global Clinical Study of Patients With Early Alzheimer’s Disease

Retrieved on: 
Friday, December 2, 2022

ANAVEX2-73 met the primary endpoints ADAS-Cog1 and ADCS-ADL2 and key secondary endpoint CDR-SB3 with statistically significant results.

Key Points: 
  • ANAVEX2-73 met the primary endpoints ADAS-Cog1 and ADCS-ADL2 and key secondary endpoint CDR-SB3 with statistically significant results.
  • ANAVEX2-73 treatment met the primary endpoints and reduced clinical decline on the global cognitive and functional scales over 48 weeks in the analysis of the Intent-to-treat (ITT) population.
  • ANAVEX2-73 demonstrated visible improvement in patients with Alzheimers disease.
  • On average, patients, who improved cognitively with ANAVEX2-73 treatment, improved by ADAS-Cog cognition score of -4.03 points.

Brazilian Regulatory Authority Grants Approval for Waylivra™ for Familial Partial Lipodystrophy

Retrieved on: 
Thursday, December 1, 2022

SOUTH PLAINFIELD, N.J., Dec. 1, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the Brazilian Health Regulatory Agency, ANVISA (Agência Nacional de Vigilância Sanitária), has approved Waylivra™ (volanesorsen) as the first treatment for familial partial lipodystrophy (FPL) in Brazil. This is the first approval globally for Waylivra for the FPL indication. Waylivra is also approved in Brazil for the treatment of Familial Chylomicronemia Syndrome (FCS).

Key Points: 
  • SOUTH PLAINFIELD, N.J., Dec. 1, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the Brazilian Health Regulatory Agency, ANVISA (Agncia Nacional de Vigilncia Sanitria), has approved Waylivra (volanesorsen) as the first treatment for familial partial lipodystrophy (FPL) in Brazil.
  • This is the first approval globally for Waylivra for the FPL indication.
  • Waylivra is also approved in Brazil for the treatment of Familial Chylomicronemia Syndrome (FCS).
  • ANVISA's approval for Waylivra for FPL was based on results from the Phase 2/3 BROADEN study in patients with familial partial lipodystrophy.

Cognition Therapeutics Presents Scientific Rationale, Clinical Biomarker and Preclinical Data supporting a Phase 2 Clinical Trial with CT1812 in Geographic Atrophy Secondary to Dry AMD

Retrieved on: 
Thursday, December 1, 2022

Complement inhibition has shown potential in clinical trials but must be given via intravitreal injection to each affected eye.

Key Points: 
  • Complement inhibition has shown potential in clinical trials but must be given via intravitreal injection to each affected eye.
  • CT1812 is an experimental oral sigma-2 (-2) receptor modulator currently in Phase 2 clinical trials for both Alzheimer's disease and dementia with Lewy bodies (DLB).
  • The proteomic analyses from our clinical studies in neurodegenerative disease were instrumental in identifying dry AMD as an indication of interest, explained Mary Hamby, Ph.D. , VP of biology at Cognition Therapeutics.
  • We are currently investigating our lead candidate CT1812 in clinical programs in Alzheimers disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD).

Memory Fitness Among Fastest-Growing Medicare Advantage Benefits

Retrieved on: 
Thursday, December 1, 2022

A recent analysis of 2022 federal data reveals that a new type of fitness benefit memory fitness is among the fastest growing preventive health benefits .

Key Points: 
  • A recent analysis of 2022 federal data reveals that a new type of fitness benefit memory fitness is among the fastest growing preventive health benefits .
  • According to Posit Science , their BrainHQ online brain fitness program is the choice of most Medicare Advantage organizations across the United States offering a memory fitness supplemental benefit.
  • It was first permitted under a regulatory change for 2019, and, starting in 2021, the government asked plans to differentiate among physical fitness (such as gym memberships), wearable fitness trackers, and memory fitness programs.
  • Our own market research indicates that mind/body fitness really resonates with older adults new to Medicare, Dr. Mahncke added.

Sanctuary Cognitive Systems receives $30 million SIF Contribution from Government of Canada to help support its mission of building general-purpose robots to address labor shortages

Retrieved on: 
Wednesday, November 30, 2022

VANCOUVER, BC, Nov. 30, 2022 /PRNewswire/ -- Sanctuary Cognitive Systems Corporation, a company on a mission to create the world's first human-like intelligence in general-purpose robots, today announced it received a $30 million SIF (Strategic Innovation Fund) Contribution, to advance its technology and address labor-related challenges in the economy.

Key Points: 
  • The contribution comes from the Government of Canada, specifically through SIF, which supports large scale, transformative and collaborative projects that help position Canada to prosper in the global knowledge-based economy.
  • SIF projects promote the long-term competitiveness of Canadian industries, clean growth, and the advancement of Canada's strategic technological advantage.
  • "Many labor-related challenges are outside the scope of current specialized AI and robotics technology," said Geordie Rose, Co-Founder and CEO of Sanctuary.
  • "We appreciate the contribution from the Government of Canada and we are working hard to make work safer, more accessible, and ultimately more productive."

NeuroPace Feasibility Study of Its RNS System for Lennox-Gastaut Syndrome Now Underway

Retrieved on: 
Wednesday, November 30, 2022

An exciting aspect of this study is that the implant location for each patient is based on customized models of their brain connectivity.

Key Points: 
  • An exciting aspect of this study is that the implant location for each patient is based on customized models of their brain connectivity.
  • Six study sites will enroll a total of 20 patients 12 years of age and older with LGS and drug-resistant generalized onset seizures.
  • [i]
    The RNS System, a paradigm-shifting treatment for drug-resistant focal epilepsy, is the only brain-responsive neuromodulation system approved by the FDA.
  • The RNS System is available at most comprehensive epilepsy centers in the United States and is widely covered by insurance.

Conagen develops high-purity non-GMO sulforaphane by bioconversion

Retrieved on: 
Tuesday, November 29, 2022

Bedford, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Expanding on its portfolio of innovative nutritional products through biotechnology, Conagen , announced the development of its 99% high-purity sulforaphane.

Key Points: 
  • Bedford, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Expanding on its portfolio of innovative nutritional products through biotechnology, Conagen , announced the development of its 99% high-purity sulforaphane.
  • Made by a proprietary bioconversion technology, the company plans to begin the commercialization path in 2023.
  • Conagens bioconversion methods enable the production of sustainable products from many naturally occurring compounds regardless of rarity or small quantities occurring in nature.
  • Sulforaphane has been associated with supporting health benefits against cancer, diabetes, digestion, and heart disease and promoting cognition.

Athira Pharma Highlights Therapeutic Potential of Fosgonimeton in Presentation of Additional Biomarker Data in Mild-to-Moderate Alzheimer’s Disease Patients from ACT-AD Phase 2 Study at CTAD Conference

Retrieved on: 
Tuesday, November 29, 2022

BOTHELL, Wash., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the presentation of additional biomarker data from the completed, exploratory ACT-AD Phase 2 study of fosgonimeton (ATH-1017) in patients with mild-to-moderate Alzheimer’s disease (AD) at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) conference.

Key Points: 
  • The late-breakingposter presentation highlights the effect of fosgonimeton treatment on biomarkers associated with neurodegeneration (NfL), neuroinflammation (GFAP, YKL-40), and Alzheimers specific protein pathologies (A 42/40 ratio and p-Tau181).
  • These additional biomarker data provide further support of the therapeutic potential of fosgonimeton in patients with mild-to-moderate Alzheimers disease, said Hans J. Moebius, M.D., Ph.D., Chief Medical Officer of Athira Pharma.
  • Furthermore, directional improvements in key biomarkers associated with Alzheimers disease pathology, A 42/40 ratio and p-Tau181, provide evidence supporting fosgonimetons potential as a disease-modifying therapy.
  • These forward-looking statements speak only as of the date hereof and Athira undertakes no obligation to update forward-looking statements.